KVUE
LONGINSIDER SELLCONGRESS BUYKENVUE INC
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
NegativeKenvue delivered modest organic sales growth (0.7% in Q1, 1.6% in Q2) with margin expansion in Q1 but contraction in Q2 due to inflation and tariffs, while missing consensus expectations in Q2 and ending a four-quarter beat streak. The pending Kimberly-Clark acquisition (expected to close Q4 2026) dominates the investment thesis, with no forward guidance provided, and a significant headwind emerged from Trump administration warnings linking acetaminophen to autism, with Tylenol representing 12-15% of earnings.
Red flags
- •Q2 2026 earnings miss on both top and bottom lines, ending four-quarter beat streak
- •Adjusted gross margin compression to 60.2% from 60.9% due to inflation, tariffs, and currency headwinds
- •Trump administration report linking acetaminophen (Tylenol) to autism risk; Tylenol represents 12-15% of earnings with stock down 20% at one point
- •No forward guidance provided due to pending acquisition, limiting visibility
- •UK group action lawsuit filed against Kenvue alleging talc-based products cause cancer
- •Organic sales growth decelerating and slowing (0.7% in Q1 to 1.6% in Q2 still modest), with volume decline in Q1
- •Stock price stagnant (up only 0.3% post-Q2 earnings to $19.23) despite positive cash flow generation
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Soros Fund Management | Soros Family Office | 3.2M | +1.9M | $54M | 0.7% | +153% | Existing |
| Point72 | Steve Cohen | 461K | +461K | $8M | <0.1% | — | NEW |
| Maverick Capital | Lee Ainslie | 92K | +92K | $2M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where KVUE ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #27 of this fund's book
- 24BERKSHIRE HATHAWAY INC DEL$64M
- 25WEC ENERGY GROUP INC$59M
- 26MEDLINE INC$57M
- 27KENVUE INC$54M
- 28COREBRIDGE FINL INC$51M
- 29BRIGHTHOUSE FINL INC$51M
- 30WEBSTER FINL CORP$49M
Values are quarter-end position sizes. Shown only for funds where KVUE ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | SC 13G/A | 19.8M | 1.0% | 2026-02-17 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Gilbert Cisneros | house | CA31 | BUY | $1,001 - $15,000 | 2026-06-16 | 2026-07-02 | ↗ |
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Earlier trades (1) — dated outside this quarter's window, not counted in the badges
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Kevin Hern | house | OK01 | SELL | $1,001 - $15,000 | 2026-08-05 | 2026-08-10 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jan 1, 2026.